Sezzle Insider Sold Shares Worth $297,629, According to a Recent SEC Filing-February 2024-www.financetom.com

Sezzle Insider Sold Shares Worth $297,629, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sezzle Insider Sold Shares Worth $297,629, According to a Recent SEC Filing

Sep 29, 2024 9:04 AM

10:03 AM EDT, 09/24/2024 (MT Newswires) -- Paul Martin Purcell, Former Director, on September 23, 2024, sold 1,800 shares in Sezzle ( SEZL ) for $297,629. Following the Form 4 filing with the SEC, Purcell has control over a total of 117,450 shares of the company, with 117,450 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1662991/000186499124000057/xslF345X05/primary_doc.xml

Price: 165.19, Change: +1.18, Percent Change: +0.72

Previous page： Cisco Systems Completes $28 Billion Acquisition of Splunk Next page： Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Cisco Systems Completes $28 Billion Acquisition of Splunk

Mar 18, 2024

11:04 AM EDT, 03/18/2024 (MT Newswires) -- Cisco Systems ( CSCO ) said Monday it has completed the acquisition of software company Splunk for $157 per share in cash or about $28 billion in equity value. The company said it expects the deal to be cash flow positive and non-GAAP gross margin accretive in its fiscal year 2025 and non-GAAP...

Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study

Mar 18, 2024

11:06 AM EDT, 03/18/2024 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Monday that it has entered into a clinical trial collaboration agreement with Bristol-Myers Squibb ( BMY ) for a melanoma combination study. The study will assess the safety and tolerability of Perspective's targeted alpha-particle therapy plus Bristol-Myers' nivolumab in patients with histologically confirmed melanoma and positive melanocortin...

Tellurian CEO Octavio Simoes to Move Into Advisory Role; Company to Explore Possible Sale -- Shares Fall

Mar 18, 2024

11:07 AM EDT, 03/18/2024 (MT Newswires) -- Tellurian (TELL) said Monday that Chief Executive Octavio Simoes will transition to an advisory role before retiring in June. The company named president of Driftwood assets, Samik Mukherjee, as president of Tellurian Investments. Mukherjee and President Daniel Belhumeur will jointly manage Tellurian's commercial activities, the company said. Meanwhile, Tellurian said in a filing...

RBC Capital Markets Notes Gran Tierra's Capital Markets Day

Mar 18, 2024

11:06 AM EDT, 03/18/2024 (MT Newswires) -- RBC Capital Markets said Monday that it Gran Tierra Energy Inc. ( GTE ) outlined its corporate strategy during its Capital Markets day presentation in Bogota. During the event, the company also presented its asset suite, key exploration opportunities and 2024 guidance/long-term plan, RBC said. Following the event, RBC said it came away...